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Deoxypodophyllotoxin (DPT) is a potential anti-tumor candidate prior to its clinical
phase. The aim of the study was to develop a physiologically based pharmacokinetic
(PBPK) model consisting of 13 tissue compartments to predict DPT disposition in
mouse, rat, monkey, and dog based on in vitro and in silico inputs. Since large
interspecies difference was found in unbound fraction of DPT in plasma, we assumed
that Kt:pl,u (unbound tissue-to-plasma concentration ratio) was identical across species.
The predictions of our model were then validated by in vivo data of corresponding
preclinical species, along with visual predictive checks. Reasonable matches were
found between observed and predicted plasma concentrations and pharmacokinetic
parameters in all four animal species. The prediction in the related seven tissues of
mouse was also desirable. We also attempted to predict human pharmacokinetic profile
by both the developed PBPK model and interspecies allometric scaling across mouse,
rat and monkey, while dog was excluded from the scaling. The two approaches reached
similar results. We hope the study will help in the efficacy and safety assessment of DPT
in future clinical studies and provide a reference to the preclinical screening of similar
compounds by PBPK model.
Keywords: deoxypodophyllotoxin, physiologically based pharmacokinetic model, interspecies allometric scaling,
unbound tissue-to-plasma concentration ratio, unbound fraction in plasma
INTRODUCTION
Deoxypodophyllotoxin (Figure 1) is an active ingredient isolated from herbs like Anthriscus
sylvestris, Pulsatilla koreana, and Podophyllum emodi (Wong et al., 2000; Khaled et al., 2013).
Accumulating evidences have demonstrated that DPT possesses a variety of pharmacological
activities, such as anti-tumor, anti-viral, anti-inflammatory, and anti-platelet aggregation effects
Abbreviations: AUC0-tn, area under the plasma concentration-time curve from time zero to last time; AUC0-∞, area under
the plasma concentration-time curve from time zero to infinity; CL, plasma clearance; DPT, deoxypodophyllotoxin; f up,
unbound fraction in plasma; Km, Michaelis–Menten constant; Kt:pl, tissue-to-plasma concentration ratio; Kt:pl,u, unbound
tissue-to-plasma concentration ratio; LC–MS/MS, liquid chromatography–tandem mass spectrometry; MRT, mean residence
time; PBPK, physiologically based pharmacokinetic; PBSF, physiological-based scaling factor; PS, permeability-surface
product; t1/2, terminal half-life; Vmax, the maximum metabolic velocity; Vss, apparent volume of distribution at steady state;
W, body weight.
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FIGURE 1 | The metabolic pathway from DPT to its main metabolites
cited from Lee et al. (2008) and Xie et al. (2016).
(Gordaliza et al., 1994; Chen et al., 2000; Jin et al., 2008),
among which anti-tumor effect is the most attractive. Its analogs
etoposide and teniposide have already been widely used for
the treatment of lung cancer, leukemia and lymphoma (Smith
et al., 1994; Baldwin and Osheroff, 2005; Wu et al., 2014).
DPT exerts its anti-tumor activity via affecting microtubule
and modulating specific cell cycle-regulatory proteins (Khaled
et al., 2013). As a promising anti-tumor candidate, DPT in an
intravenous formulation of β-cyclodextrin inclusion complex
(Zhu et al., 2010) has been developed and is undergoing its
preclinical evaluation.
Our previous study reported that DPT was rapidly eliminated
following intravenous administration to rats with a half-life
about 80–100 min (Liu et al., 2016). Another study showed that
DPT was transformed to seven metabolites in rat and human
microsomes (Lee et al., 2008). We also quantitatively described
the metabolism of DPT in hepatic microsomes of mouse,
rat, monkey, dog, and human (Xie et al., 2016). Concluding
by the metabolism studies above, DPT is mainly transformed
to demethylenated metabolite M2 and mono-hydroxylated
metabolite M7, both of which can be subsequently partly
metabolized to mono-hydroxylated, demethylenated derivative
M1 (Figure 1). M2 is major among all the metabolites. Our
preliminary experiments proved that excretion of DPT in original
form via urine and bile was less than 0.2% of the dose (4 mg/kg)
following intravenous administration to rats, with high recoveries
of M2 in the form of glucuronidated and sulfated conjugates.
Nevertheless, no relevant in vivo report of DPT in other species
was available to the best of our knowledge.
For a new candidate prior to its clinical phase, it is crucial and
meaningful to gain a prediction of its pharmacokinetic profile
in human based on the limited information from in vitro and
animal studies. PBPK model and interspecies allometric scaling
are two common methodologies for the prediction (Poulin
et al., 2011; Vuppugalla et al., 2011). Although interspecies
allometric scaling has been frequently used (Iavarone et al.,
1999; Kang et al., 2009; Sayama et al., 2013), PBPK model,
considered as a mechanism-based methodology, shows several
advantages (Pang and Durk, 2010; Poulin et al., 2011; Jones
and Rowland-Yeo, 2013). Interspecies allometric scaling highly
depends on animal study, which should be performed with
at least three animal species. However, the prediction with
PBPK model may be accomplished only from in vitro and in
silico data. PBPK model can also predict the dynamics of drug
distribution in various tissues, leading to a better understanding
of the relationship between target tissue exposure and drug
safety/efficacy.
In this study we developed a whole-body PBPK model for
the prediction of DPT disposition in four common preclinical
species (mouse, rat, monkey, and dog), with parameters from
in vitro and in silico study. After the validation by in vivo data and
visual predictive checks in corresponding species, we attempted
human pharmacokinetics projection by the model. Sensitivity
analysis was conducted on the predicted pharmacokinetic profile
in human by changing the metabolic velocity of DPT, volume
of adipose tissue, unbound fraction in plasma of DPT and
hepatic blood flow rate. Pharmacokinetic profile of DPT in
human was also predicted by Dedrick plot based on animal
data.
MATERIALS AND METHODS
Chemicals and Reagents
The analytical standard of DPT (purity 99.88%), mono-
hydroxylated metabolite M7 and β-cyclodextrin inclusion
complex of DPT (content 3.36%) were kindly supplied by
Medicinal and Chemical Institute of China Pharmaceutical
University (Nanjing, China). Diazepam (purity 99.9%) used as
internal standard was purchased from the National Institutes for
Food and Drug Control (Beijing, China). Hepatic microsomes
from mouse, rat, monkey, dog, and human were from the same
source with those in our previous study (Xie et al., 2016). All
the other reagents were of analytical grade and commercially
available.
Animals
Adult ICR mice, beagle dogs, and cynomolgus monkeys
were purchased from Sino-British SIPPR/BK Lab Animal, Ltd.
(Shanghai, China), Shanghai Jiagan Biotech, Co., Ltd (Shanghai,
China) and Hainan New Source Biotech, Co., Ltd (Haikou,
China), respectively. Animals were housed in constant room
temperature and humidity on a normal 12 h light/dark cycle.
Water and food were provided ad libitum. Animal experiments
were carried out according to institutional guidelines for
the care and the use of laboratory animals and approved
by the Animal Ethics Committee of China Pharmaceutical
University.
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Plasma Protein Binding Studies
Protein bindings of DPT in mouse, dog, and monkey plasma
were evaluated in our study by a rapid equilibrium dialysis
device (Linden Bioscience, Woburn, MA, USA) according to the
manufacturer’s instruction. Protein binding values of DPT in rat
and human plasma were obtained in a previous study by the same
approach. Dialysis experiments were initiated by adding 300 µL
of plasma containing DPT into donor cells and 500µL of 100 mM
phosphate buffer (pH 7.4) into receiver cells. After 6 h incubation
at 37◦C, the DPT concentrations in both cells were measured
based on the LC–MS/MS method previously described (Liu et al.,
2016). A preliminary study was conducted to determine the time
to reach equilibrium state. Three initial DPT concentrations (0.5,
1.5, and 4.5 µg/mL) in rat and human plasma were selected
to investigate whether non-linear binding occurred, while initial
DPT concentration in plasma of mouse, dog, and monkey was set
to be 1.0 µg/mL. All incubations were carried out in triplicate.
Kinetics of M7 Formation from DPT in
Hepatic Microsomes of Five Species
Kinetic parameters of M2, the major metabolite of DPT,
were cited from our previous report (Xie et al., 2016).
Here, the kinetics of M7 formation from DPT was depicted.
Preliminary incubations were performed to optimize the
conditions. The composition of microsomal incubation mixture
and the procedure of incubation were the same with those in
Xie et al. (2016), except that the incubation time was set to
be 5 min for all the samples and microsomal protein levels
were 0.02, 0.02, 0.05, 0.4, and 0.08 mg/mL for mouse, rat,
monkey, dog, and human microsomes, respectively. A series of
DPT concentrations from 0.0785 to 3.77 µM in microsomal
incubation system (200 µL) were adopted. Incubations of each
DPT concentration were carried out in triplicate. The formation
of M7 was determined based on the LC–MS/MS assay described
previously (Xie et al., 2016).
In vivo Pharmacokinetic Study
Pharmacokinetic profiles of DPT in rats were cited from
our previous study (Liu et al., 2016). In the present study,
pharmacokinetics of DPT in mice, monkeys, and dogs were
investigated following intravenous administration of DPT
(β-cyclodextrin inclusion complex, dissolved in 0.9% normal
saline within 2 h before administration). The dosages in the
study were designed based on the pharmacological dose in tumor
bearing mice and the toxicity in corresponding species. All
experimental animals were fasted for 12 h prior to dosing.
Mice
In the mice study 132 ICR mice of about 5 weeks old (weighing
about 20 g) were randomly divided into two groups and received
12.5 and 25.0 mg/kg of DPT via tail veins, respectively. Six mice
(three males and three females) from each group were sacrificed
at 2, 5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 min post-dose
and blood samples were collected into heparinized tubes. Heart,
liver, lung, kidney, brain, muscle, and spleen were simultaneously
collected at 5, 15, 60, and 120 min following i.v. administration
(12.5 mg/kg of DPT) to mice. The tissue samples were weighed
and homogenized in water (1:5, w/v).
Monkeys
Twelve cynomolgus monkeys of about 4 years old weighing
3.51 ± 0.85 kg were randomly divided into two groups by
each of six (three males and three females). One group received
1.0 mg/kg of DPT via cephalic vein. Two doses of DPT (0.5 and
2.0 mg/kg) were successively given to another group via cephalic
vein, separated by a 1-week washout interval. The blood samples
were collected into heparinized tubes via another cephalic vein at
pre-dose and 2, 5, 10, 20, 30, 45, 60, 90, 120, 180, and 240 min
post-dose.
Dogs
Six beagle dogs of about 10 months old (three males and three
females) weighing 8.65 ± 0.64 kg were subjected to 0.3 mg/kg
of DPT via cephalic vein and blood samples were collected into
heparinized tubes via another cephalic vein at pre-dose and 5, 15,
30, 60, 120, 180, 240, 300, 360, 420, 480, 600, 720, and 840 min
post-dose.
All blood samples were centrifuged for 5 min at 8000 g for
plasma. The plasma and tissue homogenate samples were stored
at −70◦C until analysis. DPT concentrations in plasma and
tissue homogenates were measured by the LC–MS/MS method
previously described (Liu et al., 2016).
Pharmacokinetic parameters were estimated using non-
compartmental analysis by Phoenix WinNonlin software (version
6.4, Certara, Co., Princeton, NJ, USA). The estimated main
pharmacokinetic parameters included AUC0-tn, AUC0-∞, CL,
t1/2, MRT, and Vss.
PBPK Model Development
A PBPK model (Figure 2) was constructed to describe the
pharmacokinetic profiles of DPT in five species (mouse, rat,
monkey, dog, and human). The essential structure of the model
consisted of lung, heart, spleen, gastrointestinal tract, liver,
kidney, brain, adipose, muscle, skin, arterial and venous blood,
and rest of body. Disposition of DPT in tissues was illustrated
by perfusion-rate limited model. It was assumed that DPT was
mainly eliminated in liver via M2 and M7 formation in all five
species. The differential equations were described as follows:
For non-elimination tissue compartments,
Vt
dCt
dt
= Qt × (Cart − CtKt:pl/Rbp )
where Ct, V t, Qt, and Kt:pl represent the concentration of
DPT, the volume, the blood flow rate and tissue-to-plasma
concentration ratio of corresponding tissue compartments. Cart
means the drug concentration in arterial blood compartment. Rbp
means blood-to-plasma concentration ratio, which was assumed
to be unity in the study, according to the reasons provided in
Poulin and Theil (2002).
For arterial blood compartment (subscript art),
Vart
dCart
dt
= Qtotal × ( ClunKlun:pl/Rbp − Cart)
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FIGURE 2 | Schematic diagram of whole-body PBPK model of DPT.
Arrows connecting compartments stand for the blood flows. GIT represents
gastrointestinal tract and ROB represents the rest part of body.
For venous blood compartment (subscript ven),
Vven
dCven
dt
=
∑
t
(Qt × CtKt:pl/Rbp )− Qtotal × Cven
For lung compartment (subscript lun),
Vlun
dClun
dt
= Qtotal × (Cven − ClunKlun:pl/Rbp )
where Qtotal represents the cardiac output.
And for liver compartment,
Vliv
dCliv
dt
= Qhep × Cart + Qgut ×
Cgut
Kgut:pl/Rbp
+ Qspl×
Cspl
Kspl:pl/Rbp
− (Qhep + Qgut + Qspl)×
Cliv
Kliv:pl/Rbp
− PBSF × (CLM2 + CLM7)
where subscripts liv, gut and spl refer to liver, gastrointestinal
tract and spleen, respectively. Qhep represents blood flow
rate of hepatic artery. PBSF is the amount of total hepatic
microsomal protein, which equals to the product of the
microsomal protein yield and liver weight. CLM2 and CLM7
denote the clearance via the formation of metabolite M2 and M7,
respectively.
Kt:pl of DPT in rat were estimated according to a method
previously described based on tissue composition of rat (Ruark
et al., 2014). Ionization, lipophilicity and the fraction unbound
in plasma of compound were incorporated into the calculation.
As a neutral compound, DPT was considered to be unionized
in physiological environment and the logarithm of octanol-water
partition coefficient (Log P) of DPT was calculated to be 2.68 by
Chemdraw 15.1 (PerkinElmer Informatics, Inc., Waltham, MA,
USA).
Coding and solving of the PBPK model were conducted
by Phoenix WinNonlin software (version 6.4, Certara, Co.,
Princeton, NJ, USA). Pharmacokinetic profiles of DPT in plasma
of four animal species and in tissues of mouse were predicted.
Pharmacokinetic parameters of the predicted profiles were
estimated using non-compartmental analysis. The predictions
were compared with corresponding sets of in vivo observations.
The accuracy of predicted values was assessed by fold-error
defined as follows:
If the observed value was greater than the predicted value,
fold-error was observed value divided by predicted value;
If the observed value was less than the predicted value, fold-
error was predicted value divided by observed value.
The fold-error less than two denoted a successful prediction.
The validated PBPK model was subsequently applied to predict
pharmacokinetic profile in human.
Visual Predictive Checks of the Model
To validate the model in animal populations, we assumed
that inter-individual variability existed in hepatic blood flow
rate and metabolic velocity of DPT. We introduced inter-
individual variability by exponential model and intra-individual
variability by multiplicative residual error model, to simulate the
pharmacokinetic profiles in animal populations. The first order
conditional estimation of Lindstrom-Bates (FOCE L-B) method
was used in the simulation. All values of parameters listed in
Tables 1 and 2 as well as unbound fraction in plasma of DPT
were regarded as typical values and fixed during the simulation,
while the variances of hepatic blood flow rate and metabolic
velocity (regarded as random effect parameters) together with
standard deviation of intra-individual error were estimated. The
constructed population models were subsequently subjected to
visual predictive checks based on 1000 times of simulations.
The 5, 50, and 95th percentiles of the simulations were plotted
along with the observed data for visual inspection. Simulation
and validation of the population models were performed on
Phoenix NLME module (version 1.3, Certara, Co., Princeton, NJ,
USA).
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Sensitivity Analysis
The previous study showed M2 formation from DPT in human
microsomes was mainly mediated by CYP2C9 and CYP2C19
(Xie et al., 2016), which were reported to exhibit marked inter-
individual variability in their expression and catalytic activity
(Hirota et al., 2013). In addition, DPT possessed high adipose-
to-plasma concentration ratio and high plasma protein binding.
Therefore, the sensitivity analysis was conducted to evaluate the
impacts of alterations in metabolic velocity of DPT, adipose
volume, unbound fraction of DPT in plasma and hepatic blood
flow rate on pharmacokinetic behavior of DPT in human. The
variation was set to be 10-fold for metabolic velocity and twofold
for hepatic blood flow rate, respectively. Variations for both
adipose volume and unbound fraction in plasma were designed
to be threefold.
Interspecies Scaling by Allometric
Equation
We also tried to predict the pharmacokinetics of DPT in human
basing on the pharmacokinetics in animal species by allometric
scaling method (Dedrick et al., 1970; Boxenbaum and Ronfeld,
1983). Vss and CL of DPT across species were expressed as
follows:
Vss = α1Wβ1 andCL = α2Wβ2
where W is body weight of the corresponding species, α and β are
the coefficient and exponent, respectively. α and β values were
estimated following logarithmic / logarithmic transformation
[lg(Vss) = lg(α1)+β1lg(W) and lg(CL) = lg(α2)+β2lg(W)]
and unweighted least-squares regression analysis by IBM SPSS
software (version 19.0, IBM, Co., Armonk, NY, USA). The
plasma concentration(C)-time(t) data of DPT from different
species were graphed using Dedrick plot, in which X-axis was
physiological time t′(t′ = t/Wβ1−β2) and Y-axis was normalized
concentration C′[C′ = C/(D/Wβ1)], where D represents the
dose. The normalized concentration-physiological time data
were fitted to two-compartment model by Phoenix WinNonlin
software (version 6.4, Certara, Co., Princeton, NJ, USA). The
plasma concentration-time profile of DPT in 70 kg human
was then obtained via reverse transformation from the Dedrick
plot. The predicted concentration-time profile and the estimated
pharmacokinetic parameters in human were compared with
those by PBPK model.
RESULTS
Plasma Protein Binding of DPT in Five
Species
Human plasma protein binding values of DPT at 0.5, 1.5, and
4.5 µg/mL were 93.13 ± 0.60, 93.31 ± 0.76, and 93.88 ± 0.46%,
respectively. Rat plasma protein binding values of DPT at 0.5,
1.5, and 4.5 µg/mL were 94.39 ± 0.75, 94.52 ± 0.50, and
94.91 ± 0.33%, respectively. These results proved that DPT
possessed high affinity to plasma protein and the binding was
linear within the tested concentrations. The average protein
binding values of DPT at the tested three concentrations in
human and rat plasma were 93.44 and 94.61%, respectively.
Protein binding values of DPT in mouse, monkey and dog plasma
were 97.17± 0.25, 99.19± 0.03, and 99.84± 0.03%, respectively.
Notable interspecies difference was observed in unbound fraction
of DPT in plasma, which varied from 6.56% in human to 0.16%
in dog.
PBPK Model Development and Validation
PBPK model was developed for predicting pharmacokinetic
profiles of DPT in rats first and then extrapolated to mouse,
dog, and monkey. Kt:pl values in tissues of rat were calculated
according to the method previously described (Ruark et al.,
2014). A high Kt:pl was obtained in adipose tissue, indicating
that DPT possessed high affinity to adipose tissue. Kgut:pl was
assumed to be one in rat due to the unavailable tissue composition
of gastrointestinal tract. Given the large interspecies difference
in unbound fraction of DPT in plasma, unbound tissue-to-
plasma concentration ratio (Kt:pl,u) was incorporated in our
PBPK model. Kt:pl,u is the ratio of the concentration in tissue
to the unbound concentration in plasma, which was assumed
identical across species (Rodgers et al., 2005). Thus, Kt:pl values
in corresponding species could be derived from those of rat
(Kt:pl,rat) based on the equation Kt:pl = Kt:pl,rat × f up /f up,rat ,
where f up and f up,rat are unbound fractions of DPT in plasma of
the corresponding species and rat, respectively.
Preliminary prediction of DPT concentrations in brain of mice
demonstrated a significant overestimation using the perfusion-
rate limited model, therefore brain model was refined to be a
permeability-limited model as follows:
V1
dC1
dt
= Qbra(Cart − C1)− PS(C1 − C2/Kbra:pl)
and
V2
dC2
dt
= PS(C1 − C2/Kbra:pl)
where C and V are the concentration of DPT and compartment
volume, respectively. Subscript 1 and 2 denote vascular
and extravascular compartment, respectively. Qbra and Kbra:pl
represent the blood flow rate of brain and brain-to-plasma
concentration ratio, respectively. PS is the permeability-surface
product of DPT in brain and the value of mouse (PSmouse) was
estimated by fitting the model to brain concentration data. The
PS values in brain of other species (PSi) were then scaled from
data of mouse by the following equation (Hu et al., 2014):
PSi = PSmouse × ( WiWmouse )
0.67
where Wi and Wmouse are the body weights of the corresponding
species and mouse, respectively.
CLM2 and CLM7 were obtained from the previous and the
present study, respectively. For the clearance via M2 formation:
CLM2 =
∑ Vmax ,i,M2 × fup × Cliv/Kliv:pl
Km,i,M2 + fup × Cliv/Kliv:pl
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TABLE 2 | Metabolic parameters of five species used in PBPK model.
Mouse Rat Monkey Dog Human
PBSF∗(mg protein/body) 49.28 409.92 5270.40 16592.70 82472.00
Km1,M2 (µM) 1.81 0.05 0.08 0.09 0.24
Vmax1,M2 (nmol/min/mg protein) 3.43 4.93 0.40 0.03 0.32
Km2,M2 (µM) \ \ 2.26 9.47 \
Vmax2,M2 (nmol/min/mg protein) \ \ 1.02 0.10 \
Km,M7 (µM) 1.21 1.27 0.31 0.52 1.53
Vmax,M7 (pmol/min/mg protein) 42.76 150.03 31.86 2.64 24.38
γ 1.55 1.55 1.78 1.45 1.22
∗The microsomal protein yields in mouse, rat, monkey, dog, and human were 44.8, 44.8, 48.8, 77.9, and 48.8 mg protein/g liver, respectively, according to Naritomi et al.
(2001). The data of mouse and monkey were assumed to be equal to those of rat and human, respectively. PBSF was the product of the microsomal protein yield and
the liver weight in Table 1.
where Km,i,M2, and Vmax,i,M2 are kinetic parameters of the
metabolism from DPT to M2 in hepatic microsomes and were
cited from our previous report (Xie et al., 2016).
For the clearance via M7 formation, since the kinetics
exhibited auto-activation features (Figure 3), a Hill equation was
used to characterize the kinetics:
CLM7 = Vmax,M7 × (fup × Cliv/Kliv:pl)
γ
Kγm,M7 + (fup × Cliv/Kliv:pl)γ
where Km,M7, Vmax,M7 and γ are kinetic parameters and Hill
coefficient estimated from the kinetics of M7 formation in the
present study.
All parameters used in the PBPK model were listed in Tables 1
and 2. The predictions were validated by in vivo pharmacokinetic
data (Figures 4A–D,F).
Rats
Pharmacokinetic profiles of DPT in rat following intravenous
administration (1.0, 2.0, and 4.0 mg/kg) were predicted by
the developed PBPK model (Figure 4A) and corresponding
pharmacokinetic parameters were obtained (Table 3). As seen in
Figure 4A and Table 3, the predicted pharmacokinetic profiles
and parameters were in line with the observations in our previous
report (Liu et al., 2016). Fold-errors of all concentration data
and parameters were less than two, indicating that the prediction
was successful in rat. It was also found that DPT possessed high
plasma clearance (close to the rate of hepatic blood flow) in rats,
accompanied by a terminal half-life of 80–100 min and a volume
of distribution above threefold body volume.
Mice
The developed PBPK model in rat was extrapolated to mouse.
Plasma concentration-time profiles of DPT following intravenous
administration (12.5 and 25.0 mg/kg) were predicted (Figure 4B)
and corresponding pharmacokinetic parameters were estimated
(Table 3). The predictions were further compared with in vivo
data (Figure 4B; Table 3). In vivo results showed that the AUC
values were proportional to dose levels. CL values were estimated
to be 70.76 and 67.73 mL/min/kg for 12.5 and 25.0 mg/kg,
respectively, suggesting that clearance of DPT in mice was in a
dose-independent manner at the tested dose levels. It was also
found that DPT exhibited a moderate plasma clearance in mice
(about 70% of hepatic blood flow), with an associated t1/2 of
about 40–60 min and a Vss of about double of the body volume.
The predicted pharmacokinetic profiles were comparable to
the observed profiles, and the fold-errors of all the predictive
parameters were less than two, implying a successful prediction.
Concentrations of DPT in heart, liver, lung, muscle, brain,
kidney, and spleen of mouse following intravenous injection
(12.5 mg/kg) were simultaneously predicted and the prediction
was validated by the actual observations at 5, 15, 60, and 120 min
following dosing (Figures 5A–G). The exposures (AUC0-120 min)
from the predicted profiles in the related tissues of mouse were in
good agreement with the in vivo values, with fold-errors less than
two (Figure 5H).
Monkeys
The developed PBPK model in rat was then extrapolated to
monkey. The plasma concentration-time curve of DPT in
monkeys following intravenous administration of 0.5, 1.0, and
2.0 mg/kg were predicted (Figure 4C) and the pharmacokinetic
parameters were estimated (Table 3). In vivo pharmacokinetics
indicated that plasma clearance of DPT in monkeys trended
downward when the dose level increased, but no significant
difference was observed. In monkeys, DPT exhibited a moderate
to high CL (66–90% of hepatic blood flow), with a t1/2 ranging
from 32 to 58 min and a Vss slightly higher than total body
volume. The predicted pharmacokinetic profiles by PBPK model
were consistent with the in vivo data. The pharmacokinetic
parameters estimated from the predicted profiles were within
twofold error of the observed data except Vss and MRT. The
results demonstrated that the prediction in monkey was desirable.
Dogs
The developed PBPK model in rat was further extrapolated to
dog. Plasma concentration-time data of DPT (i.v. 0.3 mg/kg)
were predicted and further validated by in vivo data (Figure 4D;
Table 3). The observed results revealed that the disposition of
DPT in dogs was greatly different from the other three species.
In dogs, DPT exhibited a very low CL (only 3.4% of hepatic blood
flow), a long t1/2 of 187 min and a low Vss (0.35 L/kg). However,
the developed PBPK model still gave an appropriate prediction
for pharmacokinetic profile of DPT in dogs. All the predicted
pharmacokinetic parameters were within twofold error of the
observed values.
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FIGURE 3 | Kinetic profiles of M7 formation in liver microsomes from (A) mouse, (B) rat, (C) monkey, (D) dog, and (E) human. The insets are Eadie–Hofstee
plots of the kinetic profiles. Dots and error bars represent the mean value and standard deviation of observed data at each DPT concentration, respectively (n = 3).
Lines denote the simulated kinetic curves.
Visual Predictive Checks of the Model
Visual predictive checks of the model in four animal species of
the corresponding dose group were presented in Figure 6. In
each check, most of the observed data located within the area
between the 5 and 95th percentiles of the simulations, while the
median of observed data approached the 50th percentile of the
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FIGURE 4 | Observed and predicted plasma concentration-time profiles of DPT in rats (A) (n = 10), mice (B) (n = 6), monkeys (C) (n = 6), and dogs (D)
(n = 6). Dots and error bars represent the mean value and standard deviation of observed data at each time point, respectively. Lines denote the predicted plasma
concentration-time profiles. (E) Compares the human plasma concentration-time profiles of DPT predicted by Dedrick plot and PBPK model. (F) Represents the
relationship of mean observed and predicted plasma concentration of DPT at each time point in four animal species, in which solid and dashed lines indicate unity
and twofold errors between predicted and observed data, respectively.
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simulations, suggesting that the deviation between observed data
and predicted profiles was reasonable and could be characterized
by the simulated population. The virtual trial simulation plots
validated that good predictions were achieved by our model for
the four species.
Predicted Pharmacokinetic Profile of
DPT in Human
After developing and validating the PBPK model in the four
preclinical species, we attempted to predict pharmacokinetic
profile of DPT in human. Kt:pl values in human were also
derived from rat based on the assumption that Kt:pl,u values were
equivalent. Since no clinical information of DPT was reported,
the dose for simulation in 70 kg human was assumed to be
16 mg according to the safety evaluation in monkeys, whose
maximum tolerated dose was determined to be 4 mg/kg. The
plasma concentration-time profile in human from 0 to 240 min
after intravenous administration of 16 mg DPT was predicted
(Figure 4E) and the pharmacokinetic parameters were estimated
(Table 3). The predicted results showed that DPT exhibited a high
CL of 1.39 L/min (close to hepatic blood flow) in human, with a
t1/2 of 70.22 min and a Vss close to total body volume (61.94 L).
Sensitivity Analysis
Impacts of alterations in hepatic metabolic velocity of DPT,
adipose volume, unbound fraction of DPT in plasma, and hepatic
blood flow rate on the predicted pharmacokinetic behavior in
human were documented (Figure 7). It was consistent with
our expectation that metabolic velocity remarkably affected
the exposure of DPT in human. When metabolic velocity
was reduced to 1/10, AUC0-∞ increased to about 2.2-fold,
accompanied by a fall in CL by 53.7%. However, when metabolic
velocity was increased to 10-fold, AUC0-∞ only decreased to
86.2% of the original value, with an increase in CL of 16.0%.
Tripled adipose tissue volume diminished AUC0-∝ by 20.1%,
while raised Vss by 43.7% and t1/2 by 40.0%. Slight variations
in parameters were found when volume of adipose tissue was
changed to 1/3 of the initial value. Unbound fraction of DPT
in plasma prominently affected t1/2 and Vss. Threefold unbound
fraction led to remarkable augments in t1/2 and Vss to 224.1 and
246.7% of the control values, respectively, while AUC0-∝ and CL
altered little. When unbound fraction in plasma was set to be 1/3
of initial value,CL decreased to 68.8% of the control, with t1/2 and
AUC0-∝ rising by 123.2 and 45.3%, respectively, while Vss slightly
changed. Within our expectation, halved hepatic blood flow rate
remarkably reduced CL to 61.6% and raised AUC0-∝ to 162.4%
of the original data, respectively, displaying the characteristic of
high hepatic extraction ratio drug.
Interspecies Allometric Scaling
The observed CL and Vss of each species were incorporated to
perform interspecies allometric scaling. It is generally accepted
that CL (mL/min) and Vss (L) increase with the rising body
weight across species, whereas the parameters of DPT in dogs
did not obey the rule. CL (10.94 mL/min) and Vss (3.05 L) in
dogs were lower than those in monkeys (CL 113.39 mL/min
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FIGURE 5 | Observed and predicted concentration-time profiles of DPT in heart (A), liver (B), lung (C), kidney (D), brain (E), muscle (F), and spleen (G) of
mice (12.5 mg/kg, n = 6). Dots and error bars represent the mean value and standard deviation of observed data at each time point, respectively. Lines represent
the predicted concentration-time profiles. (H) Represents the relationship of observed and predicted AUC0-120 min of DPT in the tissues above, in which solid and
dashed lines indicate unity and twofold errors between predicted and observed data, respectively.
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FIGURE 6 | The visual predictive checks of predicted plasma concentration-time profiles of DPT in 2.0 mg/kg rats (A), 12.5 mg/kg mice (B), 1.0 mg/kg
monkeys (C), and 0.3 mg/kg dogs (D). Dots represent the observed individual data. Solid lines represent the 50th percentiles and dashed lines represent the 5 and
95th percentiles of the simulated populations.
and Vss 4.40 L, mean value of three dose groups), even though
mean body weight of dogs (8.65 kg) was larger than that of
monkeys (3.51 kg). Correction by unbound fraction of DPT in
plasma might partly improve interspecies scaling of Vss, but did
not improve scaling profile of CL. Neither maximum lifespan
potential nor brain weight correction (Mahmood et al., 2006)
substantially altered the scaling profile of CL. All these results
demonstrated that dog seemed not to be suitable for interspecies
scaling in the study. Therefore, interspecies scaling was carried
out only across mouse, rat and monkey. Equations describing
the relationship between the related parameters and body weight
(W) across mouse, rat and monkey were CL = 44.28W0.832
and Vss = 1.99W0.857, respectively (units: CL: mL/min; Vss:
L; W: kg). Their correlations were fairly good (r2 > 0.91)
(Figures 8A,B). The estimated human CL and Vss based on
allometric equation were 1.52 L/min and 75.65 L. Dedrick plot
was generated across the three species, in which X axis was time
divided by W0.857−0.832 and Y axis was concentration divided
by (dose/W0.857). Plasma concentration-time data from mice,
rats, and monkeys of all dose groups were used in the animal
scale-up study. As seen in Figures 8C,D, the concentration-
time profiles of DPT in three species are close to each other
after being transformed. The mixed profile was further fitted
to two-compartment model (resulted C′ = 1.495e−0.164t ′+
0.156e−0.012t ′ , units: C′: µg/mL; t′: min). Plasma concentration-
time profile following intravenous administration of 16 mg DPT
in human (70 kg) was predicted by reverse transformation from
the model above and a two-compartment model equation of
C = 0.628e−0.147t + 0.066e−0.011t (units: C: µg/mL; t: min) was
obtained (Figure 4E), from which pharmacokinetic parameters of
human were estimated. The estimated AUC0-∝, CL, Vss, and t1/2
from Dedrick plot were 10.25 µg·min/mL, 1.56 L/min, 87.67 L
and 63.08 min, respectively, which were close to the results by
PBPK model.
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FIGURE 7 | The effects of changing metabolic velocity (A), adipose volume (B), unbound fraction in plasma (fup) (C), and hepatic blood flow rate (D) in human
PBPK model on predicted human plasma concentration-time profile of DPT.
DISCUSSION
As a potential anti-tumor candidate, DPT is undergoing
preclinical evaluation up to date. Mouse, rat, monkey and dog are
the most frequently used preclinical species. In this study a PBPK
model was established to predict pharmacokinetic behaviors of
DPT in all the four species above. The validated model was
further used to predict pharmacokinetics of DPT in human.
Although, PBPK model may complete the prediction based
on parameters obtained from in vitro and in silico data,
many cases of predictions were still dependent on animal
experiments, which supplied necessary parameters such as Kt:pl
and CL for simulation (Hudachek and Gustafson, 2013; Hao
et al., 2014; Hu et al., 2014; Bi et al., 2016). Since one of
the most important applications of PBPK model is to make
prediction prior to in vivo experiments (especially clinical trials),
qualified models relying on in vitro and in silico inputs will be
appreciated. In the present study, the PBPK model incorporated
parameters based on in vitro and in silico research and gave
reasonable predictions in various preclinical species, indicating
the application of the model in the human pharmacokinetics
projection.
Several in silico methods to estimate Kt:pl have been reported
(Poulin and Theil, 2002; Berezhkovskiy, 2004; Rodgers and
Rowland, 2006; Schmitt, 2008; Peyret et al., 2010; Ruark
et al., 2014). In the present study, Kt:pl values in rat were
calculated using the approach developed recently by Ruark et al.
(2014), which was considered to provide a more comprehensive
tissue composition model than previous approaches. In a
previous attempt we employed Kt:pl values of rat throughout
the models, resulting in poor predictions in the other three
animals, which might be due to large interspecies difference
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FIGURE 8 | The interspecies allometric scaling of DPT across mouse, rat and monkey and corresponding Dedrick plots. The regression analyses of
mean CL (A) and Vss (B) of each dose group against body weight (W) were performed after log-log transformation across mouse, rat, and monkey. Dog’s data were
not involved in the regression due to the low CL and Vss. The lines represent the regression lines across mouse, rat and monkey. (C) Mean plasma concentration
normalized by dose (mg) per body weight (kg)-time profiles of DPT in mouse, rat, and monkey of each dose group. (D) Mean plasma concentration-time profiles of
DPT in mouse, rat, and monkey of each dose group after transformation by Dedrick’s approach. The line denotes the pharmacokinetic curve simulated from the
mixed profile.
in unbound fraction of DPT in plasma (from 5.39% in rat
to 0.16% in dog). Correction of Kt:pl from rat by unbound
fraction of DPT in plasma greatly improved the predictions
in the other three species. Preliminary prediction showed an
overestimation of DPT concentrations in brains of mice, which
might be partly attributed to the restricted penetration of DPT
through blood brain barrier. Introduction of the permeability-
limited model into brain greatly improved the accuracy of
prediction.
According to the previous study (Xie et al., 2016), DPT is
mainly metabolized to M2 and M7 in liver microsomes of five
species, both of which are further transformed to M1. Calculated
by the data obtained in (Xie et al., 2016), the summed amount of
M1, M2, and M7 formation counted for 84.7, 86.5, and 75.0% of
DPT depletion in mouse, rat, and dog microsomes, respectively,
after incubation of 60 min, while in monkey and human
microsomes the data approached 100%. Thus, we assumed that
DPT was eliminated through M2 and M7 formation in our PBPK
model. The kinetics of M7 formation were studied and suggested
auto-activation characteristics in microsomes of all species,
which was diagnosed by the “hook” shapes in corresponding
Eadie–Hofstee plots (Houston and Kenworthy, 2000). In human
microsomes the sigmoidal kinetics of M7 was less obvious, with a
relatively small γ value (1.22). Compared with M7, M2 formation
was the major metabolic pathway of DPT in all species. It was seen
from the estimated metabolic parameters (Table 2) thatCLM2 was
approximately at least fifty times larger than CLM7, indicating
that the contribution of M7 formation to DPT elimination was
minor.
Given the reasonable prediction in all four animal species,
the developed PBPK model was further applied to characterize
pharmacokinetics of DPT in human. The predicted CL
(1.39 L/min) was close to hepatic blood flow rate, showing
that DPT was subjected to high hepatic extraction in human.
DPT was reported to be mainly metabolized to M2 in human
hepatic microsomes, whose intrinsic clearance was up to
1.38 mL/min/mg protein (Xie et al., 2016). This might be a reason
for the short elimination half-life (70.22 min) in human. The
predicted Vss was 61.94 L (close to total body volume), implying
that DPT was extensively distributed in body.
Sensitivity analysis in human showed that the decrease in
metabolic velocity increased exposure of DPT in plasma. In
human, DPT is mainly metabolized by CYP2C9 and CYP2C19
(Xie et al., 2016), which exhibit extensive polymorphism in
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population (Hirota et al., 2013). In addition, DPT itself is a
strong inhibitor of CYP2C9 (Lee et al., 2010). Therefore, high
attention should be paid to the increased plasma exposure of
DPT due to co-administration with CYP2C inhibitors, auto-
inhibition of DPT on CYP2C9, and the administration in
CYP2C poor metabolizers in the future clinical applications.
DPT had high plasma protein affinity and variation of unbound
fraction in plasma in population might affect DPT disposition.
It was found that threefold unbound fraction led to an augment
in Vss by 146.7%, with AUC0-∝ changing slightly. However,
one third of initial unbound fraction in plasma significantly
decreased CL without affecting Vss, raising AUC0-∝ by 45.3%
subsequently. It was in line with the characteristics of a
high hepatic extraction ratio drug that CL of DPT in human
highly depended on hepatic blood flow rate. Chemotherapeutical
agents are able to induce liver injury (Ramadori and Cameron,
2010), leading to reductions in hepatic blood flow rate and
plasma protein level. These alterations may greatly change
pharmacokinetic behavior and affect safety and efficacy of
DPT.
As a mechanical and dynamic approach PBPK model
is believed more potent than interspecies allometric scaling
in the pharmacokinetics prediction. In our study, although
similar results were obtained by the two methods, interspecies
allometric scaling exhibited high dependence on animal species.
It was found that CL and Vss of DPT in dogs were not
fit for the scaling. Several efforts of correction failed, leading
to a compromise to leave out dog’s data in the scaling.
The disposition of DPT in dogs was greatly different from
other species, with a very low clearance (less than 4% of
hepatic blood flow) and low Vss (35% of body volume),
which might result from its low metabolic velocity in hepatic
microsomes (Xie et al., 2016) and high plasma protein
binding. These reasons explained why dog was not suitable
in interspecies scaling to some extent. Whereas, PBPK model
took the mechanical factors like metabolic velocity and unbound
fraction in plasma into consideration and achieved acceptable
predictions in dog, illustrating its extensive applicability in
various species.
In addition, compared with the time- and animal-
consuming approach of interspecies scaling, PBPK model
achieves prediction more economically and efficiently solely
from in vitro experiments along with literature data. It will
contribute to screening the most promising candidates with ideal
pharmacokinetic behaviors out of the substantial compounds.
The mechanism-based model can also provide information in
special populations such as children and hepatic insufficiency
patients, as with the examples in sensitivity analysis.
In summary, a whole-body PBPK model of DPT in various
species was developed mainly based on in vitro and in silico
data. The predictions were validated by in vivo pharmacokinetic
data from mice, rats, monkeys and dogs, along with visual
predictive checks. The validated PBPK model as well as allometric
interspecies scaling were tried to predict human pharmacokinetic
profiles. We expect that the prediction will be valuable for dose
selection and informative decision making during future clinical
trials, and provide a reference for the PBPK studies of similar
compounds.
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